Satisfai Health's precision imaging platform that improves the accuracy, speed and cost-effectiveness of upper and lower GI disease measurement and monitoring.

Entrust your GI research and practice to the AI platform that thinks ahead.

Access our precision imaging platform to radically improve the accuracy, speed and cost-effectiveness of upper and lower GI disease measurement and monitoring.

Request a demo

Where GI meets AI

We pair the latest advances in gastro intestinal medicine with machine learning to provide researchers and clinical practitioners with the insights needed to make informed decisions.

Research Solutions

Clinical Solutions

Complete gastro-intestinal scope We develop solutions for the detection and characterization of all major diseases in the GI tract

Workflow enhancement Our platform includes practical tools for improving common workflows in clinical practice and R&D

Multimodal data integrations Our precision platform uncovers deep insights at the intersection of endoscopy, histopathology and ultrasound

Point of care to post process Our real-time and post-process based solutions can be deployed and delivered when and where you need them

Our Precision GI Platform

Certai

Certai offers an automated quantitative assessment of Inflammatory Bowel Disease (IBD) in endoscopic video.

Curai

Curai provides an automated assessment of endoscopic video quality and scoreability.

Amicai

Amicai automates the detection (CADe) and characterization (CADx) of colon polyps (HPs, SSAs & TSAs).

Learn more

Veritai

Veritai provides real-time detection and differentiation of dysplastic and non-dysplastic Barrett’s Esophagus.

"AI has the potential to revolutionize GI endoscopy and GI practice. Satisfai Health is at the cutting edge of AI in GI, and I’m delighted and proud to be working with this company.”

Dr. Douglas K. Rex — Distinguished Professor of Medicine, Indiana University School of Medicine
“The detection, differentiation, and delineation of early GI neoplasia is a huge challenge. With the support of our AI tool, non-experts can improve their diagnostic performance to a level comparable with Barrett's experts.”

Dr. Helmut Messman — Head, Department of Internal Medicine, Augsburg Medical Centre in Germany. Past President, European Society of Gastroenterology
“Dysplasia detection within Barrett’s Esophagus can be a challenging task for even the most experienced endoscopists. Satisfai Health’s Barrett’s Dysplasia algorithm is a highly sensitive continuous real-time overlay that will help physicians conduct a high quality exam and avoid missing even the most subtle areas of dysplasia.”

Dr. Jason B. Samarasena — Associate Chief, Division of Gastroenterology and Hepatology, H. H. Chao Digestive Health Institute, University of California Irvine
"AI levels the playing field for endoscopy expertise. Every patient will receive expert level care, as with AI-support, every endoscopist can provide it.”

Dr. James East — Consultant Gastroenterologist & Endoscopist, Associate Professor of Medicine, Oxford University Hospitals NHS Foundation Trust
"It has been great to work with the SatisfAI team. Their AI endoscopy system is like having a Central Reader in your back pocket. This will improve the quality of endoscopic scoring in IBD for trials, clinical practice and training”

Dr. Simon Travis — Clinical Professor of Medicine, Oxford University
“AI has the potential to enhance the cancer-preventative attributes of colonoscopy at lower costs by increasing the detection of precancerous lesions and providing in situ pathologic diagnosis. Satisfai is well-positioned to bring these promises to rapid reality.”

Dr. William Karnes — Clinical Professor of Medicine, Director of High-Risk Program and Colonoscopy Quality, H.H. Chao Comprehensive Digestive Disease Center, University of California Irvine Medical Center
“Innovation is the beacon that guides us into uncharted territories, and Satisfai has emerged as a celestial force, illuminating the path towards a new frontier in inflammatory bowel disease. With strong external partnerships, and an unwavering common goal to transform IBD, they will emerge as a leader in the AI space.”

Dr. Remo Panaccione — Professor of Medicine & Director, Inflammatory Bowel Disease Unit , University of Calgary
“Clinical trials have many pain points, and this strategic partnership will enable advances in improving the efficiency of clinical trials and make some significant changes to how trials are run.”

Jeff Smith — CEO Alimentiv

Item 1 of 8

Satisfai Health is conducting leading research on the use of AI in evaluating patient response, driving toward a future of precision medicine and companion diagnostics that will revolutionize the way we treat IBD.

Bringing equitable access to precision GI treatment.

While the increasing number of drug approvals for Inflammatory Bowel Disease (IBD) has greatly increased options for patients, not all respond equally to the same therapies. Satisfai Health is conducting leading research on the use of AI in evaluating patient response, driving toward a future of precision medicine and companion diagnostics that will revolutionize the way we treat IBD.

Our advanced measurement capabilities help drug developers and clinicians better understand which combination of therapies and doses will make the greatest impact.